PARP1 and neoplasm: Here, we show that the radioiodinated analog [123I]CC1, an Auger electron–emitting therapeutic radiopharmaceutical that targets PARP, is exquisitely radiotoxic to PARP-expressing tumor cells and causes marked tumor growth inhibition without causing gross toxicity.